Market Cap 4.11B
Revenue (ttm) 62.38M
Net Income (ttm) -101.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -162.86%
Debt to Equity Ratio 0.00
Volume 4,762,700
Avg Vol 4,145,200
Day's Range N/A - N/A
Shares Out 144.65M
Stochastic %K 22%
Beta 1.19
Analysts Strong Sell
Price Target $40.45

Company Profile

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repress...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 320 4900
Address:
201 Brookline Avenue, Suite 901, Boston, United States
biolover
biolover Jun. 21 at 1:29 PM
As I discussed below $RVMD MGT enjoys leaking BD discussions. As significant as Daraxonrasib impact on pancreatic and other cancers .. it does help MC to have a vocal management .. I admire RVMD and was in it for years but I see more upside at this point for underdogs that have better molecules $ERAS or related $TNGX Although pharma that don’t have vision of what will be dominant in this space at 2032 could pull > $40 B deal. Examples $JNJ and MRK .. we need CEOs of suppressed biotechs such as $VKTX to engage more abs be more vocal like RVMD CEO
3 · Reply
justiceforb_85
justiceforb_85 Jun. 19 at 12:55 AM
$TNGX added more. Vopimetostat with outstanding data so far.
0 · Reply
david999957
david999957 Jun. 18 at 5:24 PM
$TNGX Dilution at 30
0 · Reply
HussainPatel
HussainPatel Jun. 18 at 4:08 PM
$TNGX lol 😂
0 · Reply
Philarney
Philarney Jun. 18 at 1:50 PM
$TNGX why minus 8.4% today ?
1 · Reply
biolover
biolover Jun. 17 at 5:56 PM
$TNGX $VSTM VSTM is not the next wave. Amazing how much retail involved in it. Many copies of the mutation specific RAS inh exits. This is not $ERAS with its scarce pan RAS molecular glue
1 · Reply
Alt_Fuel
Alt_Fuel Jun. 17 at 10:09 AM
$VSTM $TNGX 52 week low was $3.12, now at $30. Is $VSTM the next revaluation play in that space? Currently trading at $3.78, $330M market cap. Own both. Last edited 9:17 AM · Jun 8, 2026 · 7,352 Views https://x.com/doepke_michel/status/2063973709220577282
1 · Reply
biolover
biolover Jun. 16 at 10:29 AM
$TNGX this guy is screwed. This is now classic momentum stock ( actually been like that for months ). Instituons could drive MC much more than this. All eye BP M&A. It could also hit in lung ca and GBM wnd spike more. 33 M shorted shares are a curse on owners now. This what happens when retail blindly short based on percentage shorted etc. $VKTX is in line to screw up remaining short
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 15 at 10:36 PM
$TNGX Share Price: $32.89 Contract Selected: Nov 20, 2026 $30 Calls Buy Zone: $5.10 – $6.30 Target Zone: $8.45 – $10.33 Potential Upside: 56% ROI Time to Expiration: 157 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 15 at 9:23 PM
@outlawinvestor1 Sean may I ask a favor? You put together compelling data driven comparisons of bios & sometimes drugs. You recently prepared one for ACAD v PTCT & LQDA Are you able to prepare a like schedule for VSTM's VS-7375 that compares results in the clinic today to $RVMD 's Zoldonrasib & $TNGX 's Vopimetostat? Of course feel free to ignore my request if it would be too time-consuming. I always assumed you used a time-saving AI tool to prepare these comps. My employer does not allow me to install an AI tool like Claude on my PC (otherwise I'd be happy to do so myself). As you know, I generally focus on commercial-stage bios anyways. I've seen a VS-7375 comp to Zoldonrasib (RVMD's market cap is $30B+ where VTSM is not $0.5B). I otherwise hope all is well with you.
2 · Reply
Latest News on TNGX
Tango Therapeutics 18.2M share Secondary priced at $30.00

2026-06-10T10:08:24.000Z - 15 days ago

Tango Therapeutics 18.2M share Secondary priced at $30.00


Tango Therapeutics announces $500M common stock offering

2026-06-08T20:05:49.000Z - 16 days ago

Tango Therapeutics announces $500M common stock offering


Tango Therapeutics rises 45.5%

2026-06-08T16:00:09.000Z - 16 days ago

Tango Therapeutics rises 45.5%


Tango Therapeutics rises 32.1%

2026-06-08T14:07:47.000Z - 16 days ago

Tango Therapeutics rises 32.1%


Tango Therapeutics Transcript: Study result

Jun 8, 2026, 8:00 AM EDT - 16 days ago

Tango Therapeutics Transcript: Study result


Tango Therapeutics Press release: Study result

Jun 8, 2026, 8:00 AM EDT - 16 days ago

Tango Therapeutics Press release: Study result


Tango Therapeutics Slides: Study result

Jun 8, 2026, 8:00 AM EDT - 16 days ago

Tango Therapeutics Slides: Study result


Tango Therapeutics Slides: Investor presentation

Jun 8, 2026, 7:00 AM EDT - 16 days ago

Tango Therapeutics Slides: Investor presentation


Tango Therapeutics Transcript: AGM 2026

Jun 4, 2026, 9:00 AM EDT - 20 days ago

Tango Therapeutics Transcript: AGM 2026


Tango Therapeutics falls -19.7%

2026-05-15T17:52:59.000Z - 5 weeks ago

Tango Therapeutics falls -19.7%


Tango Therapeutics falls -14.9%

2026-05-15T14:19:01.000Z - 5 weeks ago

Tango Therapeutics falls -14.9%


Tango Therapeutics Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 6 weeks ago

Tango Therapeutics Quarterly report: Q1 2026


Tango Therapeutics Earnings release: Q1 2026

May 13, 2026, 7:00 AM EDT - 6 weeks ago

Tango Therapeutics Earnings release: Q1 2026


Tango Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 2 months ago

Tango Therapeutics Proxy statement: Proxy filing


Tango Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 2 months ago

Tango Therapeutics Proxy statement: Proxy filing


Tango Therapeutics Annual report: Q4 2025

Mar 5, 2026, 9:00 AM EST - 3 months ago

Tango Therapeutics Annual report: Q4 2025


Tango Therapeutics Earnings release: Q4 2025

Mar 5, 2026, 9:00 AM EST - 3 months ago

Tango Therapeutics Earnings release: Q4 2025


Tango Therapeutics Slides: Corporate presentation

Mar 5, 2026, 6:00 AM EST - 3 months ago

Tango Therapeutics Slides: Corporate presentation


Tango Therapeutics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 5 months ago

Tango Therapeutics Slides: Corporate presentation


Tango Therapeutics Appoints Sung Lee to Board of Directors

Jan 5, 2026, 7:00 AM EST - 6 months ago

Tango Therapeutics Appoints Sung Lee to Board of Directors


Tango Therapeutics Registration statement: Registration Filing

Nov 21, 2025, 7:00 AM EST - 7 months ago

Tango Therapeutics Registration statement: Registration Filing


Tango Therapeutics Earnings release: Q3 2025

Nov 4, 2025, 9:00 AM EST - 8 months ago

Tango Therapeutics Earnings release: Q3 2025


Tango Therapeutics Quarterly report: Q3 2025

Nov 4, 2025, 9:00 AM EST - 8 months ago

Tango Therapeutics Quarterly report: Q3 2025


Tango Therapeutics Transcript: Study Update

Oct 23, 2025, 8:30 AM EDT - 8 months ago

Tango Therapeutics Transcript: Study Update


Tango Therapeutics Press release: Study Update

Oct 23, 2025, 8:30 AM EDT - 8 months ago

Tango Therapeutics Press release: Study Update


Tango Therapeutics Slides: Study Update

Oct 23, 2025, 8:30 AM EDT - 8 months ago

Tango Therapeutics Slides: Study Update


Tango Therapeutics Announces $225 Million Financing

Oct 23, 2025, 7:20 AM EDT - 8 months ago

Tango Therapeutics Announces $225 Million Financing


Tango Therapeutics Quarterly report: Q2 2025

Aug 5, 2025, 9:30 AM EDT - 11 months ago

Tango Therapeutics Quarterly report: Q2 2025


Tango Therapeutics Earnings release: Q2 2025

Aug 5, 2025, 9:30 AM EDT - 11 months ago

Tango Therapeutics Earnings release: Q2 2025


Tango Therapeutics Quarterly report: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

Tango Therapeutics Quarterly report: Q1 2025


Tango Therapeutics Earnings release: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

Tango Therapeutics Earnings release: Q1 2025


Tango Therapeutics Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Tango Therapeutics Proxy statement: Proxy Filing


Tango Therapeutics Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Tango Therapeutics Proxy statement: Proxy Filing


Tango Therapeutics Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Tango Therapeutics Proxy statement: Proxy Filing


Tango Therapeutics Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Tango Therapeutics Proxy statement: Proxy Filing


Tango Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Tango Therapeutics Earnings release: Q4 2024


Tango Therapeutics Annual report: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Tango Therapeutics Annual report: Q4 2024


Tango Therapeutics Quarterly report: Q3 2024

Nov 6, 2024, 7:00 AM EST - 1 year ago

Tango Therapeutics Quarterly report: Q3 2024


Tango Therapeutics Earnings release: Q3 2024

Nov 6, 2024, 7:00 AM EST - 1 year ago

Tango Therapeutics Earnings release: Q3 2024


Tango Therapeutics Quarterly report: Q2 2024

Aug 7, 2024, 7:00 AM EDT - 2 years ago

Tango Therapeutics Quarterly report: Q2 2024


Tango Therapeutics Earnings release: Q2 2024

Aug 7, 2024, 7:00 AM EDT - 2 years ago

Tango Therapeutics Earnings release: Q2 2024


Tango Therapeutics Slides: Corporate Presentation

Jun 11, 2024, 7:00 AM EDT - 2 years ago

Tango Therapeutics Slides: Corporate Presentation


Tango Therapeutics to stop development of cancer therapy

May 23, 2024, 7:19 AM EDT - 2 years ago

Tango Therapeutics to stop development of cancer therapy


Tango Therapeutics Announces Discontinuation of TNG348 Program

May 23, 2024, 7:00 AM EDT - 2 years ago

Tango Therapeutics Announces Discontinuation of TNG348 Program


Tango Therapeutics Quarterly report: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Tango Therapeutics Quarterly report: Q1 2024


Tango Therapeutics Earnings release: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Tango Therapeutics Earnings release: Q1 2024


Tango Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Tango Therapeutics Proxy statement: Proxy Filing


Tango Therapeutics Proxy statement: Proxy Filing

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Tango Therapeutics Proxy statement: Proxy Filing


Tango Therapeutics Earnings release: Q4 2023

Mar 18, 2024, 7:00 AM EDT - 2 years ago

Tango Therapeutics Earnings release: Q4 2023


Tango Therapeutics Annual report: Q4 2023

Mar 18, 2024, 7:00 AM EDT - 2 years ago

Tango Therapeutics Annual report: Q4 2023


Tango Therapeutics Slides: Corporate Presentation

Nov 13, 2023, 7:00 AM EST - 2 years ago

Tango Therapeutics Slides: Corporate Presentation


Tango Therapeutics Quarterly report: Q3 2023

Nov 8, 2023, 7:15 AM EST - 2 years ago

Tango Therapeutics Quarterly report: Q3 2023


Tango Therapeutics Earnings release: Q3 2023

Nov 8, 2023, 7:15 AM EST - 2 years ago

Tango Therapeutics Earnings release: Q3 2023


Tango Therapeutics Announces Updates to Its Board of Directors

Aug 29, 2023, 5:08 PM EDT - 3 years ago

Tango Therapeutics Announces Updates to Its Board of Directors


Tango Therapeutics Quarterly report: Q2 2023

Aug 7, 2023, 7:00 AM EDT - 3 years ago

Tango Therapeutics Quarterly report: Q2 2023


Tango Therapeutics Earnings release: Q2 2023

Aug 7, 2023, 7:00 AM EDT - 3 years ago

Tango Therapeutics Earnings release: Q2 2023


Tango Therapeutics Quarterly report: Q1 2023

May 9, 2023, 8:00 AM EDT - 3 years ago

Tango Therapeutics Quarterly report: Q1 2023


Tango Therapeutics Earnings release: Q1 2023

May 9, 2023, 8:00 AM EDT - 3 years ago

Tango Therapeutics Earnings release: Q1 2023


biolover
biolover Jun. 21 at 1:29 PM
As I discussed below $RVMD MGT enjoys leaking BD discussions. As significant as Daraxonrasib impact on pancreatic and other cancers .. it does help MC to have a vocal management .. I admire RVMD and was in it for years but I see more upside at this point for underdogs that have better molecules $ERAS or related $TNGX Although pharma that don’t have vision of what will be dominant in this space at 2032 could pull > $40 B deal. Examples $JNJ and MRK .. we need CEOs of suppressed biotechs such as $VKTX to engage more abs be more vocal like RVMD CEO
3 · Reply
justiceforb_85
justiceforb_85 Jun. 19 at 12:55 AM
$TNGX added more. Vopimetostat with outstanding data so far.
0 · Reply
david999957
david999957 Jun. 18 at 5:24 PM
$TNGX Dilution at 30
0 · Reply
HussainPatel
HussainPatel Jun. 18 at 4:08 PM
$TNGX lol 😂
0 · Reply
Philarney
Philarney Jun. 18 at 1:50 PM
$TNGX why minus 8.4% today ?
1 · Reply
biolover
biolover Jun. 17 at 5:56 PM
$TNGX $VSTM VSTM is not the next wave. Amazing how much retail involved in it. Many copies of the mutation specific RAS inh exits. This is not $ERAS with its scarce pan RAS molecular glue
1 · Reply
Alt_Fuel
Alt_Fuel Jun. 17 at 10:09 AM
$VSTM $TNGX 52 week low was $3.12, now at $30. Is $VSTM the next revaluation play in that space? Currently trading at $3.78, $330M market cap. Own both. Last edited 9:17 AM · Jun 8, 2026 · 7,352 Views https://x.com/doepke_michel/status/2063973709220577282
1 · Reply
biolover
biolover Jun. 16 at 10:29 AM
$TNGX this guy is screwed. This is now classic momentum stock ( actually been like that for months ). Instituons could drive MC much more than this. All eye BP M&A. It could also hit in lung ca and GBM wnd spike more. 33 M shorted shares are a curse on owners now. This what happens when retail blindly short based on percentage shorted etc. $VKTX is in line to screw up remaining short
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 15 at 10:36 PM
$TNGX Share Price: $32.89 Contract Selected: Nov 20, 2026 $30 Calls Buy Zone: $5.10 – $6.30 Target Zone: $8.45 – $10.33 Potential Upside: 56% ROI Time to Expiration: 157 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 15 at 9:23 PM
@outlawinvestor1 Sean may I ask a favor? You put together compelling data driven comparisons of bios & sometimes drugs. You recently prepared one for ACAD v PTCT & LQDA Are you able to prepare a like schedule for VSTM's VS-7375 that compares results in the clinic today to $RVMD 's Zoldonrasib & $TNGX 's Vopimetostat? Of course feel free to ignore my request if it would be too time-consuming. I always assumed you used a time-saving AI tool to prepare these comps. My employer does not allow me to install an AI tool like Claude on my PC (otherwise I'd be happy to do so myself). As you know, I generally focus on commercial-stage bios anyways. I've seen a VS-7375 comp to Zoldonrasib (RVMD's market cap is $30B+ where VTSM is not $0.5B). I otherwise hope all is well with you.
2 · Reply
mohamettarik
mohamettarik Jun. 15 at 2:36 PM
$TNGX pure manipulation ... dirty work started ... institutions hands. short selling all the way to $11
1 · Reply
Jhoooon
Jhoooon Jun. 14 at 3:54 PM
$BMEA Think about the investor who held $TNGX at $1.03 in May 2025. Overwhelmed by the endless FUD (Fear, Uncertainty, Doubt) from shorts and bad actors on Stocktwits, they panic-sold out of sheer desperation. Exactly one year later, the stock is trading at $32 because the underlying science was always real. The level of regret must be unbearable. What does that person think now about the manipulative scammers who convinced them to sell? It’s a brutal reminder: trust the data, not the noise. Same thing now applies to $BMEA, near its lowest but science is effective. Just a question of weeks/months before it starts flying.
2 · Reply
mohamettarik
mohamettarik Jun. 14 at 2:23 AM
$TNGX unfortunately, most of investors got cheated by such pumping.. We was closely observing this stock since 4 months... Very small orders with pumping.. And when itbwas about to correct and go down, they released the news to continue the tragedy.. Now they achieved the target of offering.. Time for institutions to sell for short sellers.... Going to $11 over 1 year again... Save my post
0 · Reply
JFais
JFais Jun. 13 at 9:51 PM
$TNGX - well that went well (one year later) $RVMD
0 · Reply
FonsieTrader
FonsieTrader Jun. 12 at 1:38 PM
$TNGX The breakout happened. Now the chart is doing something even more important: It's holding the breakout. After a powerful expansion move, price is consolidating above prior resistance while buyers continue defending every dip. That's typically what strong stocks do before the next move. --> Higher lows intact --> Support holding --> Momentum still constructive --> Volume remains elevated The strongest charts don't go straight up. They advance. They consolidate. They advance again. As long as the breakout zone continues acting as support, I remain very constructive on the bigger picture. Watching for the next leg higher. $TNGX #Biotech #MomentumStocks
0 · Reply
mohamettarik
mohamettarik Jun. 12 at 12:48 AM
$TNGX TNGX this company is big scam. I am sure of corruption. Not logic this SP valuation vs competitors.. Look at running biotech with millions of revenues and price below $5.
0 · Reply
Chauncy_Peppertooth
Chauncy_Peppertooth Jun. 11 at 8:13 PM
$TNGX uh oh…
0 · Reply
focafoca99
focafoca99 Jun. 10 at 9:33 PM
$TNGX underwrites a $566.5 million offering of common stock and pre‑funded warrants.
1 · Reply
Autolus_Freakk
Autolus_Freakk Jun. 10 at 7:46 PM
$TNGX Safe level to enter??
1 · Reply
HussainPatel
HussainPatel Jun. 10 at 3:22 PM
$TNGX And down she goes!!!
1 · Reply
HussainPatel
HussainPatel Jun. 10 at 3:09 PM
0 · Reply
ashleystubblefielda
ashleystubblefielda Jun. 10 at 3:08 AM
$VMHG Victory Marine Holdings Announces Completion of Initial GUTSI(TM) Production and U.S. Market Launch https://www.accessnewswire.com/newsroom/en/agriculture/victory-marine-holdings-announces-completion-of-initial-gutsitm-production-and-u.s.-mar-1170673 $USO $DKNG $TNGX
0 · Reply